Apolipoprotein e polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the genetics of lipid lowering and diet network (GOLDN) study

Circulation: Cardiovascular Genetics

Volumn 3, Issue 5, 2010, Pages 462-467

  Irvin, Marguerite R ^a   Kabagambe, Edmond K ^a   Tiwari, Hemant K ^b   Parnell, Laurence D ^c   Straka, Robert J ^d   Tsai, Michael ^e   Ordovas, Jose M ^c   Arnett, Donna K ^a  

^a Public Health   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c TUFTS UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apolipoproteins; Genetics; Lipids

Indexed keywords

APOLIPOPROTEIN E; FENOFIBRATE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ALLELE; ARTICLE; DIET RESTRICTION; FAMILY RELATION; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID DIET; MAJOR CLINICAL STUDY; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; APOLIPOPROTEINS E; DIETARY FATS; FASTING; FEMALE; FENOFIBRATE; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 78649370520     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.110.950667     Document Type: Article

References (42)

1. Hodis HN, Mack WJ, Krauss RM, Alaupovic P. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects. Clin Cardiol. 1999;22:II15-II20.
2. Yuan G, Al Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176:1113-1120.
3. Dergunov AD. Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo-and hy-pertriglyceridemia. Biochemistry (Mosc). 2004;69:720-737.
4. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155:487-495.
5. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
6. de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat. 1994;4:178-194.
7. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J. 1987;113:433-440.
8. Utermann G, Kindermann I, Kaffarnik H, Steinmetz A. Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet. 1984;65:232-236.
9. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141:137-147.
10. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298:1300-1311.
11. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham Offspring Study. JAMA. 1994;272:1666-1671.
12. Ward H, Mitrou PN, Bowman R, Luben R, Wareham NJ, Khaw KT, Bingham S. APOE genotype, lipids, and coronary heart disease risk: a prospective population study. Arch Intern Med. 2009;169:1424-1429.
13. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res. 1992;33:447-454.
14. Vansant G, Mertens A, Muls E. Determinants of postprandial lipemia in obese women. Int J Obes Relat Metab Disord. 1999;23(suppl 1):14-21.
15. Brisson D, Ledoux K, Bosse Y, St Pierre J, Julien P, Perron P, Hudson TJ, Vohl MC, Gaudet D. Effect of apolipoprotein E, peroxisome proliferator-ac- tivated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics. 2002;12:313-320.
16. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther. 2006;11:211-221.
17. Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics. 2004;14:823-829.
18. Corella D, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, Hixson JE, Straka RJ, Province M, Lai CQ, Parnell LD, Borecki I, Ordovas JM. The - 256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. Clin Chem. 2007;53:1144-1152.
19. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
20. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48:171-180.
21. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31: 545-548.
22. GaudermanWJand MorrisonJM. QUANTO1.1: acomputerprogramfor power and sample size calculations for genetic-epidemiology studies. 2009. Available at: http://hydra.usc.edu/gxe.
23. Chung WK, Patki A, Matsuoka N, Boyer BB, Liu N, Musani SK, Goropashnaya AV, Tan PL, Katsanis N, Johnson SB, Gregersen PK, Allison DB, Leibel RL, Tiwari HK. Analysis of 30 genes (355 SNPS) related to energy homeostasis for association with adiposity in European-Am and Yup'ik Eskimo populations. Hum Hered. 2009;67:193-205.
24. Frikke-Schmidt R, Nordestgaard BG, Agerholm-Larsen B, Schnohr P, Tybjaerg-Hansen A. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res. 2000;41:1812-1822.
25. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
26. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol. 2009;24:345-350.
27. Wallace JP, Johnson B, Padilla J, Mather K. Postprandial lipaemia, oxidative stress and endothelial function: a review. Int J Clin Pract. 2010;64:389-403.
28. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol. 2000;11:615-620.
29. Luc G, Bard JM, Arveiler D, Evans A, Cambou JP, Bingham A, Amouyel P, Schaffer P, Ruidavets JB, Cambien F. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction: the ECTIM Study. Arterioscler Thromb. 1994;14:1412-1419.
30. Tiret L, deKnijff P, MenzelH J, Ehnholm C, NicaudV,Havekes LM. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations: the EARS Study: European Atherosclerosis Research Study. Arterioscler Thromb. 1994;14:1617-1624.
31. Mahley RW, Palaoglu KE, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V, Onat H, Fulks P, Mahley LL, Vakar F. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res. 1995;36:839-859.
32. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985;37:268-285.
33. Cardona F, Morcillo S, Gonzalo-Marin M, Tinahones FJ. The apoli-poprotein E genotype predicts postprandial hypertriglyceridemia in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2005; 90:2972-2975.
34. Kobayashi J, Saito Y, Taira K, Hikita M, Takahashi K, Bujo H, Morisaki N, Saito Y. Effect of apolipoprotein E3/4 phenotype on postprandial triglycerides and retinyl palmitate metabolism in plasma from hyperlip-idemic subjects in Japan. Atherosclerosis. 2001;154:539-546.
35. Reiber I, Mezo I, Kalina A, Palos G, Romics L, Csaszar A. Postprandial triglyceride levels in familial combined hyperlipidemia: the role of apolipoprotein E and lipoprotein lipase polymorphisms. J Nutr Biochem. 2003;14:394-400.
36. Reznik Y, Morello R, Pousse P, Mahoudeau J, Fradin S. The effect of age, body mass index, and fasting triglyceride level on postprandial lipemia is dependent on apolipoprotein E polymorphism in subjects with non-insulin- dependent diabetes mellitus. Metabolism. 2002;51:1088-1092.
37. Dallongeville J, Tiret L, Visvikis S, O'Reilly DS, Saava M, Tsitouris G, Rosseneu M, DeBacker G, Humphries SE, Beisiegel U. Effect of apo E phenotype on plasma postprandial triglyceride levels in young male adults with and without a familial history of myocardial infarction: the EARS II study: European Atherosclerosis Research Study. Atherosclerosis. 1999;145:381-388.
38. Smith JA, Arnett DK, Kelly RJ, Ordovas JM, Sun YV, Hopkins PN, Hixson JE, Straka RJ, Peacock JM, Kardia SL. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur J Hum Genet. 2008;16:603-613.
39. Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol. 2003;92:794-797.
40. Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK. Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 2010;10:138-148.
41. ScottR,O'BrienR,FulcherG,PardyC,D'EmdenM,TseD,TaskinenMR, Ehnholm C, Keech A. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493-498.
42. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257:2518-2521.